FIELD: medicine; neurology.
SUBSTANCE: invention relates to medicine, namely to neurology; it can be used for the treatment of neuropathic pain. The method includes the administration of a natural component obtained from marine organisms – ethanolamide docosahexaenoic acid (hereinafter – EA-DHA) subcutaneously in the form of a water-fat emulsion at a dose of 4 mg/kg for 5 weeks every day.
EFFECT: use of the invention allows for the treatment of neuropathic pain and its cognitive and emotional consequences due to suppression of neural inflammation in the hippocampus, enhancing neurogenesis, reduction in activation of microglia, and release of anti-inflammatory cytokines under action of EA-DHA.
1 cl, 17 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEUROPATHIC PAIN REDUCTION MEDICATION | 2017 |
|
RU2659202C1 |
| METHOD FOR STIMULATING NEUROGENESIS IN THE HIPPOCAMPUS | 2017 |
|
RU2675111C2 |
| AGENT STIMULATING NEUROGENESIS IN ISCHEMIC CEREBRAL INJURIES | 2015 |
|
RU2585094C1 |
| BRAIN CORTEX MOTONEURONS GROWTH STIMULATOR FOR GROWING MAMMAL AND METHOD OF APPLICATION THEREOF | 2007 |
|
RU2348421C2 |
| COMBINATIONS OF PALMITOYLETHANOLAMIDE FOR TREATING CHRONIC PAIN | 2018 |
|
RU2701720C1 |
| ACTIVE DRUG INGREDIENT, DRUG, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF DEMYELINATING DISEASES OF LIVING ORGANISM, INCLUDING DISEASE PREVENTION | 2015 |
|
RU2631887C2 |
| MODULATOR OF NMDA-RECEPTOR WITH STABILISED SECONDARY STRUCTURE AND ITS USAGE | 2011 |
|
RU2566821C2 |
| 4-(3-((2-ADAMANTYL)AMINO)-3-OXOPROP-1-EN-1-YL)-N-HYDROXYBENZAMIDE - A NEW DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 2022 |
|
RU2783995C1 |
| INTERLEUKIN-10, USING IT AND BASED COMPOSITION FOR TREATING BRAIN NEURODEGENERATIVE PROCESSES | 2012 |
|
RU2538613C2 |
| NEW APPLICATION | 2004 |
|
RU2416426C2 |
